Unlock stock picks and a broker-level newsfeed that powers Wall Street.
ASX - Delayed Quote AUD

TrivarX Limited (TRI.AX)

Compare
0.0120
0.0000
(0.00%)
At close: April 4 at 4:10:38 PM GMT+11
Loading Chart for TRI.AX
  • Previous Close 0.0120
  • Open 0.0120
  • Bid 0.0110 x --
  • Ask 0.0120 x --
  • Day's Range 0.0110 - 0.0120
  • 52 Week Range 0.0110 - 0.0450
  • Volume 2,246,351
  • Avg. Volume 801,247
  • Market Cap (intraday) 6.843M
  • Beta (5Y Monthly) 0.88
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date Feb 28, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Mount Lawley, Australia.

trivarx.com

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: TRI.AX

View More

Performance Overview: TRI.AX

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .

YTD Return

TRI.AX
0.00%
S&P/ASX 200 [XJO] (^AXJO)
6.02%

1-Year Return

TRI.AX
60.00%
S&P/ASX 200 [XJO] (^AXJO)
1.36%

3-Year Return

TRI.AX
86.67%
S&P/ASX 200 [XJO] (^AXJO)
2.05%

5-Year Return

TRI.AX
91.43%
S&P/ASX 200 [XJO] (^AXJO)
51.31%

Compare To: TRI.AX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TRI.AX

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    6.84M

  • Enterprise Value

    6.23M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.60

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -22.05%

  • Return on Assets (ttm)

    -2.41%

  • Return on Equity (ttm)

    -4.44%

  • Revenue (ttm)

    2M

  • Net Income Avi to Common (ttm)

    -440.2k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    808.54k

  • Total Debt/Equity (mrq)

    1.71%

  • Levered Free Cash Flow (ttm)

    -2.18M

Research Analysis: TRI.AX

View More

Company Insights: TRI.AX

Research Reports: TRI.AX

View More

People Also Watch